Journal of Clinical Psychopharmacology最新文献_第9页

Noncardiac Chest Pain and Hypertensive Urgency During Long-term Intravenous Racemic Ketamine for Treatment-Resistant Depression. 长期静脉外消旋氯胺酮治疗难治性抑郁症期间的非心源性胸痛和高血压急症。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2025-01-01 Epub Date: 2024-11-18 DOI: 10.1097/JCP.0000000000001939

Liliana Patarroyo-Rodriguez, Jennifer L Vande Voort, Simon Kung, Sarah K Brown, Stefanie Cavalcanti, Matthew J Ritter, Balwinder Singh

引用次数: 0

The Treatment of Iatrogenic Anorgasmia in a Male Patient on Clozapine for Treatment-Resistant Schizophrenia: The Role of Pseudoephedrine. 治疗一名服用氯氮平治疗难治性精神分裂症的男性患者的先天性性高潮：伪麻黄碱的作用。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2025-01-01 Epub Date: 2024-11-12 DOI: 10.1097/JCP.0000000000001930

Paul O'Connell, Mohamed Alsaffar

引用次数: 0

Recurrent Pancreatitis Associated With Atomoxetine Use in a 9-Year-Old Boy: A Case Report. 9岁男孩使用托莫西汀并发胰腺炎复发1例报告。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2025-01-01 Epub Date: 2024-11-29 DOI: 10.1097/JCP.0000000000001938

Ömer Faruk Bulut, Ali Karayağmurlu

引用次数: 0

Ethics in Psychedelic Science: Promises and Responsibilities. 迷幻科学的伦理：承诺与责任。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2025-01-01 Epub Date: 2024-11-27 DOI: 10.1097/JCP.0000000000001944

Dominic Sisti

引用次数: 0

Quality Assurance of Depression Ratings in Psychiatric Clinical Trials. 精神病学临床试验中抑郁评分的质量保证。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2025-01-01 Epub Date: 2024-11-21 DOI: 10.1097/JCP.0000000000001936

Michael T Sapko, Cortney Kolesar, Ian R Sharp, Jonathan C Javitt

{"title":"Quality Assurance of Depression Ratings in Psychiatric Clinical Trials.","authors":"Michael T Sapko, Cortney Kolesar, Ian R Sharp, Jonathan C Javitt","doi":"10.1097/JCP.0000000000001936","DOIUrl":"10.1097/JCP.0000000000001936","url":null,"abstract":"Background: Extensive experience with antidepressant clinical trials indicates that interrater reliability (IRR) must be maintained to achieve reliable clinical trial results. Contract research organizations have generally accepted 6 points of rating disparity between study site raters and central \"master raters\" as concordant, in part because of the personnel turnover and variability within many contract research organizations. We developed and tested an \"insourced\" model using a small, dedicated team of rater program managers (RPMs), to determine whether 3 points of disparity could successfully be demonstrated as a feasible standard for rating concordance.Methods: Site raters recorded and scored all Montgomery-Åsberg Depression Rating Scale (MADRS) interviews. Audio files were independently reviewed and scored by RPMs within 24 to 48 hours. Concordance was defined as the absolute difference in MADRS total score of 3 points or less. A MADRS total score that differed by 4 or more points triggered a discussion with the site rater and additional training, as needed.Results: In a sample of 236 ratings (58 patients), IRR between site ratings and blinded independent RPM ratings was 94.49% (223/236). The lowest concordance, 87.93%, occurred at visit 2, which was the baseline visit in the clinical trial. Concordance rates at visits 3, 4, 5, and 6 were 93.75%, 96.08%, 97.30%, and 100.00%, respectively. The absolute mean difference in MADRS rating pairs was 1.77 points (95% confidence interval: 1.58-1.95). The intraclass correlation was 0.984 and an η2 = 0.992 (F = 124.35, P < 0.0001).Conclusions: Rigorous rater training together with real-time monitoring of site raters by RPMs can achieve a high degree of IRR on the MADRS.","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":"45 1","pages":"28-31"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142877238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Question: What Are the Latest Guidelines for Treating Individuals With Body Dysmorphic Disorder? 问题：治疗身体畸形障碍的最新指南是什么？

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2025-01-01 Epub Date: 2024-11-22 DOI: 10.1097/JCP.0000000000001945

Katharine A Phillips

引用次数: 0

Efficacy and Safety of Dose Increase From 40 mg/d to 80 mg/d of Lurasidone in Patients With Schizophrenia: A Post Hoc Analysis of Extension Trial. 精神分裂症患者鲁拉西酮剂量从40mg /d增加到80mg /d的有效性和安全性：一项扩展试验的事后分析

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2025-01-01 Epub Date: 2024-12-02 DOI: 10.1097/JCP.0000000000001943

Hiroyoshi Takeuchi, Hiroyuki Uchida

{"title":"Efficacy and Safety of Dose Increase From 40 mg/d to 80 mg/d of Lurasidone in Patients With Schizophrenia: A Post Hoc Analysis of Extension Trial.","authors":"Hiroyoshi Takeuchi, Hiroyuki Uchida","doi":"10.1097/JCP.0000000000001943","DOIUrl":"10.1097/JCP.0000000000001943","url":null,"abstract":"Objectives: The primary objective of this study was to evaluate the efficacy and safety of increasing the dose of lurasidone from 40 mg/d to 80 mg/d in patients with schizophrenia.Methods: This post hoc analysis focused on patients who completed a 6-week double-blind, placebo-controlled trial of lurasidone and transitioned to a subsequent 12-week open-label extension trial. Patients initially assigned to lurasidone (40 mg/d) or placebo during the double-blind trial (DBT-LUR group or DBT-PLA group, respectively) received lurasidone (40 mg/d) during the extension. Clinicians could increase the dose to 80 mg/d based on clinical judgment. The efficacy outcomes included the change in the Positive and Negative Syndrome Scale (PANSS) total score from the start to the end of the lurasidone (80 mg/d) treatment period. Safety outcome was the rate of newly emergent adverse events.Results: Of 287 patients in the intention-to-treat population, 153 received an increased dose of lurasidone from 40 mg/d to 80 mg/d. Significant reductions in the PANSS total scores were observed in both groups (all P values, ≤0.001). Additionally, 35.9% of the DBT-LUR group and 40.0% of the DBT-PLA group achieved a ≥20% reduction in the PANSS total score. New adverse events emerged in 47.4% of the DBT-LUR group and 48.0% of the DBT-PLA group during the lurasidone (80 mg/d) treatment period.Conclusions: Increasing the dose of lurasidone from 40 mg/d to 80 mg/d may be effective and well tolerated in patients with schizophrenia. Because of the lack of a control group and blinding, the results should be interpreted with caution.","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"16-19"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142769484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Agitated Depression and the Potential Response to Gama-Amino Butyric Acid Agonist: A Case Series and Literature Review. 激动性抑郁和对γ -氨基丁酸激动剂的潜在反应：一个病例系列和文献综述。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2025-01-01 Epub Date: 2024-11-26 DOI: 10.1097/JCP.0000000000001935

Rawan Alhau, Motaz Rimawi, Izabela Zubrzycka, Yassir Mahgoub

{"title":"Agitated Depression and the Potential Response to Gama-Amino Butyric Acid Agonist: A Case Series and Literature Review.","authors":"Rawan Alhau, Motaz Rimawi, Izabela Zubrzycka, Yassir Mahgoub","doi":"10.1097/JCP.0000000000001935","DOIUrl":"10.1097/JCP.0000000000001935","url":null,"abstract":"Purpose/background: Agitated depression is a specific variant of depressive disorder characterized by marked psychomotor agitation, including prominent restlessness and pacing, intense anxiety, irritability, and insomnia. These symptoms can be severe, and patients might be at increased risk of suicide. Authors have suggested that agitated depression can worsen with the use of antidepressants but can respond to options such as electroconvulsive therapy (ECT), lithium, anticonvulsants, antipsychotics, and benzodiazepines. Appropriate identification of this variant of depressive disorder is essential for proper treatment, as some of these patients might be labeled as resistant to treatment due to the worsening or lack of response to several antidepressant trials.Methods/procedure: Summary of 2 recent cases and literature review on agitated depression symptoms and treatment.Finding/results: Our 2 patients presented with symptoms of depressed mood, increased anxiety, irritability, poor sleep, poor appetite, restlessness, rumination, indecisiveness, and psychosis. Both patients had worsening symptoms with the use of various antidepressants but improved with the use of lorazepam and olanzapine. We review literature describing this variant of depressive disorder and its suggested treatment.Implication/conclusion: Agitated depression has been poorly characterized in the literature. The criteria suggested by Koukopoulos et al (Acta Psychiatr Scand. 2007;115:50-57) and the provisional criteria for melancholia, as indicated by Mahgoub et al (Front Psychiatry. 2024;15:1372136), might help recognize this variant of depressive disorder. These patients might have a poor response or worsen with the use of antidepressants while responding to options like gamma-amino butyric acid (GABA) agonists, antipsychotics, and ECT.","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":"45 1","pages":"32-36"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142877227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

α-PVP Associated Psychosis: A Case Report. α-PVP相关精神病1例报告

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2024-11-01 DOI: 10.1097/JCP.0000000000001918

Irene Perez-Sagaseta de Ilurdoz, Alicia Aparicio-Dominguez, Silvia Yelmo-Cruz, Cesar Cardenes-Moreno

引用次数: 0

Myocarditis on Clozapine 50 mg/d in a Patient With Parkinson's Disease. 帕金森病患者服用氯氮平 50 毫克/天后出现心肌炎。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2024-11-01 DOI: 10.1097/JCP.0000000000001927

Luisa Skoble, Stephen Kutz, Joseph H Friedman

引用次数: 0